Global Anti-Aging Market Trends and Insights
Aging Population Expansion
The global population aged 65 and above grew from 732.9 million in 2020 to 854.6 million in 2025. That increase of 121.7 million, or 16.6%, enlarges the potential audience for products addressing age-related appearance concerns. For manufacturers of anti-wrinkle products, demographic expansion offers a source of potential demand beyond switching buyers between brands. For device suppliers, the relevant commercial question is how much additional treatment capacity providers would need if more older adults seek skin-tightening procedures. This makes aging a long-term demand driver whose commercial effect depends on converting a broader population into product users or treatment recipients.Rising Demand For Minimally-Invasive Aesthetic Procedures
A growing skin-tightening service business can increase demand for the equipment used to deliver treatment, connecting patient activity with an aesthetic supplier's commercial opportunity. Based on its plastic-surgeon survey, the International Society of Aesthetic Plastic Surgery (ISAPS) estimated 1.53 million non-surgical skin-tightening procedures worldwide in 2025, up 23.3% from 2024. The Aesthetic Society describes radiofrequency, intense pulsed light or broad band light, and ultrasound among the equipment options surgeons select for non-surgical skin tightening. The availability of several modalities means the same treatment category can generate demand for different equipment, depending on the surgeon's selected approach. Procedure growth consequently expands the clinical workload open to device suppliers, and each modality's supplier competes for the share of that workload that surgeons assign to it.Stringent Multi-Region Cosmetic Regulations
Access to European Union cosmetic buyers depends on meeting legal entry conditions before a supplier can monetize demand for its anti-aging range. EU cosmetics rules require a product safety report before market placement and an EU-designated responsible person for products placed on the EU market. These obligations make both product documentation and local legal accountability part of the commercial launch decision for manufacturers entering the bloc. In its 2025 staff review, the European Commission reported cosmetics-industry stakeholder concerns that accelerating CLP classifications require reformulations and can lead to discontinuing products that cannot be reformulated or would suffer significant performance compromises. Reformulation therefore adds a potential post-launch burden to pre-market compliance, with the risk of losing a product's commercial life when acceptable performance cannot be preserved.Other drivers and restraints analyzed in the report include:
- Growing Male Grooming & Self-Care Spend
- AI-Driven Personalized Skin-Care Algorithms
- Adverse Effects & Efficacy Skepticism
Segment Analysis
Anti-wrinkle products accounted for a 29.84% share of the anti-aging market size in 2026. Shiseido's ELIXIR main wrinkle-cream series ranked first by estimated series sales value in Japan's wrinkle-improving medicated skincare cosmetics category for 8 consecutive years from May 2017 through April 2025, according to INTAGE SRI+ data. That duration demonstrates a sustained commercial position for a product franchise centered on a specific skin concern. A rival topical brand in Japan's wrinkle-care category must therefore overcome a franchise that held first place by estimated series sales value for 8 consecutive years.Dermal fillers and injectables are the fastest-growing segment, with a forecast CAGR of 9.55% over 2027-2032. In its preliminary 2025 results, Hugel reported global dermal-filler net sales of KRW 129.7 billion (USD 91.2 million), demonstrating an established commercial base for the category. On August 11, 2026, Galderma received EU Medical Device Regulation approval for Restylane Shaype, a hyaluronic acid injectable for temporary chin augmentation. Sunscreen and UV absorbers address a preventive opportunity, with the American Academy of Dermatology's 2026 survey finding 21% of Americans unaware sunscreen helps prevent premature aging. Injectable expansion can thus come from authorizing additional treatment uses, while sunscreen suppliers face the separate task of explaining prevention.
Radio-frequency devices represented a 26.92% anti-aging market share in 2026. The largest segment includes Thermage, a monopolar radiofrequency skin-tightening system supplied by Solta Medical, Bausch Health's aesthetics business. Solta Medical reported that cumulative Thermage-family tip sales exceeded 5 million worldwide by September 2025. New radiofrequency entrants therefore compete against a tightening platform with a substantial cumulative tip-sales base.
Laser and light-based devices are the fastest-growing segment, with a forecast CAGR of 10.05% over 2027-2032. El.En. Group's broader aesthetic-systems revenue rose 11.02% year over year in the first half of 2026, including anti-aging lasers and microwave-based Onda Pro, while hair-removal sales declined. Bausch Health and Solta Medical announced the Canadian launch of Clear + Brilliant Touch on February 23, 2026, following Health Canada approval on May 20, 2025. These routes give laser suppliers a choice between expanding the applications served within an aesthetic portfolio and extending an authorized system into another national provider market.
Complete Report Scope:
- By Product Type
- Anti-wrinkle Products
- Anti-stretch-mark Products
- Hair-color Products
- Sunscreen & UV Absorbers
- Dermal Fillers & Injectables
- By Device Type
- Radio-frequency Devices
- Laser & Light-based Devices
- Micro-dermabrasion Devices
- Ultrasound & Plasma Devices
- By Application
- Anti-wrinkle Treatment
- Anti-pigmentation
- Skin Resurfacing & Texture
- Cellulite Reduction
- By Distribution Channel
- Hyper-/Super-markets
- Specialty Stores & Clinics
- E-commerce
- By End-user
- At-home
- Dermatology Clinics
- Hospitals & Surgery Centers
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 36.71% of the anti-aging market size in 2026, making it the largest region. In 2025, AbbVie reported US revenue of USD 1.5 billion for Botox Cosmetic and USD 385 million for the Juvederm Collection. These product-level revenues demonstrate a substantial US commercial base for aesthetic injectables, giving the region's lead a concrete supplier-sales context. Botox Cosmetic revenue declined 10.5% from 2024, while Juvederm Collection revenue declined 18% over the same period. The scale of these US injectable franchises provides a commercial foundation for North America's lead even as their sales decline.Asia-Pacific is the fastest-growing region, with a forecast CAGR of 9.6% over 2027-2032. Sisram Medical reported Asia-Pacific group revenue of USD 78.4 million in the first half of 2026, up 19.1% year over year. Sisram's broader portfolio spans energy-based medical aesthetic devices, injectables and complementary solutions, so its Asia-Pacific revenue is tied to both device placements and injectable sales.
In Europe, skin care was the largest cosmetics and personal-care product category by retail sales value in 2025. Within South America, Brazil recorded 2.36 million surgical aesthetic procedures in 2025, the most surgical procedures of any country in ISAPS's plastic-surgeon survey. In the Middle East and Africa, ISAPS's 2025 survey identified Tunisia among the countries with the highest proportions of foreign patients for aesthetic procedures. European topical suppliers can address an established consumer skincare category, while Brazil's surgical activity makes professional providers relevant customers for treatment-related supply. The foreign-patient mix in Tunisia also makes local resident counts an incomplete guide to the patient base served by its aesthetic providers.
List of Companies Covered in this Report:
- L'Oréal SA
- Estée Lauder Companies Inc.
- Procter & Gamble
- Unilever PLC
- Beiersdorf
- Abbvie
- Shiseido Co. Ltd.
- Kenvue Inc. (Neutrogena)
- Galderma
- Coty Inc.
- Amorepacific Corp.
- Bausch Health
- Lumenis
- Cynosure Lutronic, Inc. (Cynosure)
- Cutera
- Merck
- L'Oréal SA (Aesop)
- LVMH (Maison Christian Dior)
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- L'Oréal SA
- Estée Lauder Companies Inc.
- Procter & Gamble Co.
- Unilever PLC
- Beiersdorf AG
- AbbVie Inc. (Allergan Aesthetics)
- Shiseido Co. Ltd.
- Kenvue Inc. (Neutrogena)
- Galderma SA
- Coty Inc.
- Amorepacific Corp.
- Bausch Health Companies Inc. (Solta Medical)
- Lumenis Be Ltd.
- Cynosure Lutronic, Inc. (Cynosure)
- Cutera Inc.
- Merck KGaA
- L'Oréal SA (Aesop)
- LVMH (Maison Christian Dior)

